Peptides for Female Libido: PT-141, Kisspeptin, and the Evidence Gap
Female libido is influenced by brain signaling, hormones, physical comfort, medications, sleep, stress, mood, health, and relationship context. Peptides can affect some of these pathways, but only one option has a defined FDA-approved role for low desire in women.
- Desire vs arousal
- PT-141
- Kisspeptin
- Pain and dryness
- Medication effects
- How libido treatments compare
- What to ask a provider
PT-141 Has the Clearest Clinical Status
Bremelanotide, also known as PT-141 and sold by prescription as Vyleesi, is approved for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. It is an as-needed medication and works through melanocortin receptors rather than simply increasing genital blood flow.
The Indication Is Narrower Than “Low Libido”
The diagnosis excludes low desire primarily explained by a medical or psychiatric condition, relationship problems, or medication or substance effects. It also does not mean the drug is approved for every postmenopausal woman or every episode of reduced interest.
Kisspeptin Is an Interesting Research Area
Kisspeptin is deeply involved in reproductive neuroendocrine signaling and has been studied experimentally in relation to sexual and emotional brain processing. That does not make commercially sold kisspeptin an approved libido treatment.
Why Pain and Dryness Change the Answer
Low interest may be secondary to pain, vulvovaginal symptoms, pelvic-floor dysfunction, endometriosis, or fear of discomfort. A desire-focused drug cannot substitute for identifying and treating pain.
Medication and Health Review
Antidepressants and other medications can affect desire or arousal. Depression, anxiety, thyroid disease, sleep disorders, and chronic illness can also contribute. A sexual-health evaluation is broader than a hormone test.
The Sourcing Distinction
Prescription bremelanotide from a licensed prescriber and pharmacy is not equivalent to research-grade PT-141 purchased from a peptide vendor. Identity, dosing, labeling, sterility, and monitoring matter.
Products labeled for research use are not approved for self-treatment. When an approved prescription pathway exists, work through a licensed clinician and legitimate pharmacy.
For laboratory research only. These products are not approved for self-treatment or human consumption.
Frequently Asked Questions
Not sure which peptide fits your goal?
Take the 60-second quiz for a personalized educational starting point.
Take the Quiz →Compare this guide with our menopause, perimenopause, women-over-40, female libido, PT-141 approval, BPC-157, NAD+, and peptide-delivery explainers. These pages are designed to answer different versions of the same question without pretending one peptide fits every woman.
Menopause peptides · Perimenopause peptides · Peptides for women over 40 · Female libido peptides · Is PT-141 FDA approved? · BPC-157 for women · NAD+ and perimenopause · Oral vs injectable peptidesRelated Reading
FDA compounding safety information: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
FDA compounding Q&A: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
National Institute on Aging menopause overview: https://www.nia.nih.gov/health/menopause/what-menopause
Vyleesi prescribing label: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=BREMELANOTIDE